Vyzulta has been approved in Mexico for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, Nicox announced in a press release.
Bausch + Lomb, Nicox’s partner, received the approval for Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) from Mexican authorities.
It has previously been approved in the United States and Canada.
“Vyzulta is now approved in three major markets. This approval will contribute to Nicox revenue stream, and it validates that Nicox is continuing to maximize the value from our partnered assets to complement our own development activities, further reinforced by our recent Zerviate license in South Korea and the forthcoming commercial launch of Zerviate in the U.S. by our partner Eyevance,” Gavin Spencer, Nicox chief business officer, said in the release.
Nicox receives tiered net royalties of Vyzulta global sales, as well as milestone payments, from Bausch + Lomb.